Xenon Pharmaceuticals (XENE) EBT (2013 - 2026)

Xenon Pharmaceuticals (XENE) has reported EBT for 14 consecutive years, with -$104.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 62.29% year-over-year to -$104.9 million; the TTM figure through Mar 2026 stood at -$391.3 million (down 53.15% YoY), while the FY2025 annual figure was -$351.1 million, down 47.25% from the prior year.
• EBT grew to -$104.9 million in Q1 2026 per XENE's latest filing, from -$110.9 million in the prior quarter.
• Across five years, EBT topped out at -$20.1 million in Q1 2022 and bottomed at -$110.9 million in Q4 2025.
• Historically, EBT has averaged -$59.0 million across 5 years, with a median of -$48.6 million in 2023.
• Annual changes were most pronounced in 2022 — EBT plunged 141.13% — and 2024, when it retreated 14.68%.
• Xenon Pharmaceuticals' EBT stood at -$36.3 million in 2022, then decreased by 23.97% to -$44.9 million in 2023, then sank by 54.7% to -$69.5 million in 2024, then sank by 59.48% to -$110.9 million in 2025, then increased by 5.43% to -$104.9 million in 2026.
• Business Quant data shows XENE's EBT at -$104.9 million in Q1 2026, -$110.9 million in Q4 2025, and -$90.2 million in Q3 2025.